L. Wernevik

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

G. Johnsson, U. Eriksson, A. Bylock, 2006, Clinical pharmacokinetics.

An oral antisense oligonucleotide for PCSK9 inhibition

P. Gennemark, B. Monia, M. Hölttä, 2021, Science Translational Medicine.

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

K. Nelander, F. Erlandsson, K. Bamberg, 2018, British journal of clinical pharmacology.

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

R. Unwin, H. Ericsson, P. Forte, 2019, Clinical and translational science.

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

C. Nilsson, I. Azarov, C. Dota, 2022, British journal of clinical pharmacology.

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

K. Bamberg, I. Squire, P. Greasley, 2022, Clinical and translational science.